Detalhe da pesquisa
1.
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Proc Natl Acad Sci U S A
; 116(7): 2551-2560, 2019 02 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30683722
2.
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model.
Int J Mol Sci
; 22(11)2021 May 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34070363
3.
Alkoxyallene-based syntheses of preussin and its analogs and their cytotoxicity.
Org Biomol Chem
; 17(1): 122-134, 2018 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-30520931
4.
Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
Bioorg Med Chem Lett
; 26(1): 186-93, 2016 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26611920
5.
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.
Bioorg Med Chem Lett
; 23(8): 2384-90, 2013 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23474388
6.
DNA repair inhibitors sensitize cells differently to high and low LET radiation.
Sci Rep
; 11(1): 23257, 2021 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34853427
7.
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
J Med Chem
; 64(15): 11651-11674, 2021 08 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34264057
8.
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
J Med Chem
; 64(17): 12723-12737, 2021 09 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34428039
9.
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
Cell Rep
; 36(3): 109394, 2021 07 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34289372
10.
Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.
Mol Biol Cell
; 18(10): 4024-36, 2007 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17671160
11.
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
J Med Chem
; 63(13): 7293-7325, 2020 07 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32502336
12.
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Mol Cancer Ther
; 19(1): 26-38, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31582533
13.
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.
J Med Chem
; 63(15): 8025-8042, 2020 08 13.
Artigo
Inglês
| MEDLINE | ID: mdl-32338514
14.
Off-target decoding of a multitarget kinase inhibitor by chemical proteomics.
Chembiochem
; 10(7): 1163-74, 2009 May 04.
Artigo
Inglês
| MEDLINE | ID: mdl-19350611
15.
Radiobiological effects of the alpha emitter Ra-223 on tumor cells.
Sci Rep
; 9(1): 18489, 2019 12 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31811257
16.
Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation.
Cancer Res
; 79(21): 5640-5651, 2019 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31387923
17.
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.
J Nucl Med
; 60(9): 1293-1300, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30850485
18.
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo.
Clin Cancer Res
; 25(4): 1404-1414, 2019 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30429199
19.
Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models.
Signal Transduct Target Ther
; 3: 9, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29666673
20.
Identification of Atuveciclib (BAYâ 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
ChemMedChem
; 12(21): 1776-1793, 2017 11 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28961375